Teva (TEVA) calls active after patent board says certain claims of Copaxone patent invalid
- European stocks hit three-week low as Trump reality sets in
- Qualcomm (QCOM) Calls Apple's (AAPL) Claims 'Baseless'
- Unease over Trump sends dollar to one-and-half month low
- Kate Spade (KATE) Said to Attract Interest from Coach (COH) and Michael Kors (KORS) - Bloomberg
- Oil falls as signs of U.S. output rise overshadow OPEC-led cuts
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Teva Pharma (NYSE: TEVA) August 55 and 57.50 calls are active on total call volume of 25K contracts (15K puts) after the U.S. Patent and Trademark Office's Patent Trial and Appeal Board, or PTAB, determined that Mylan Pharmaceuticals (MYL) and Amneal Pharmaceuticals, as co-petitioners, met their "burden of proving the unpatentability of claims 1-20 of '250 patent by a preponderance of the evidence." August call option implied volatility is at 47, September is at 38; compared to its 52-week range of 16 to 49.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Cuts Teva Pharma (TEVA) to Neutral Amid Challenging Generic Environment
- Zions Bancorporation (ZION) call put ratio 1.9 calls to 1 put as shares near eight year high into Q4
- Stocks with Implied Volatility Movement